Burke SK - Search Results

1

Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients.

Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Chertow GM, et al. Among authors: burke sk. Nephrol Dial Transplant. 1999 Dec;14(12):2907-14. doi: 10.1093/ndt/14.12.2907. Nephrol Dial Transplant. 1999. PMID: 10570096 Clinical Trial.

2

Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.

Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. Ferramosca E, et al. Am Heart J. 2005 May;149(5):820-5. doi: 10.1016/j.ahj.2004.07.023. Am Heart J. 2005. PMID: 15894962

3

Determinants of progressive vascular calcification in haemodialysis patients.

Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Chertow GM, et al. Among authors: burke sk. Nephrol Dial Transplant. 2004 Jun;19(6):1489-96. doi: 10.1093/ndt/gfh125. Epub 2004 Apr 21. Nephrol Dial Transplant. 2004. PMID: 15102961

4

The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients.

Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, Kuhlik A, Goodman WG, Boulay A, Burke SK, Toto RD. Chertow GM, et al. Among authors: burke sk. Am J Nephrol. 2003 Sep-Oct;23(5):307-14. doi: 10.1159/000072822. Epub 2003 Aug 12. Am J Nephrol. 2003. PMID: 12915774 Clinical Trial.

5

Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.

Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM. Burke SK, et al. Adv Ren Replace Ther. 2003 Apr;10(2):133-45. doi: 10.1053/jarr.2003.50016. Adv Ren Replace Ther. 2003. PMID: 12879374

6

Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats.

Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, Burke SK, Fukushima N. Katsumata K, et al. Among authors: burke sk. Kidney Int. 2003 Aug;64(2):441-50. doi: 10.1046/j.1523-1755.2003.00126.x. Kidney Int. 2003. PMID: 12846739

7

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.

Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Chertow GM, et al. Among authors: burke sk. Kidney Int. 2002 Jul;62(1):245-52. doi: 10.1046/j.1523-1755.2002.00434.x. Kidney Int. 2002. PMID: 12081584 Clinical Trial.

8

Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing.

Fischer D, Cline K, Plone MA, Dillon M, Burke SK, Blair AT. Fischer D, et al. Among authors: burke sk. Am J Kidney Dis. 2006 Sep;48(3):437-44. doi: 10.1053/j.ajkd.2006.05.026. Am J Kidney Dis. 2006. PMID: 16931217 Clinical Trial.

9

Novel dosage forms and regimens for sevelamer-based phosphate binders.

Duggal A, Hanus M, Zhorov E, Dagher R, Plone MA, Goldberg J, Burke SK. Duggal A, et al. Among authors: burke sk. J Ren Nutr. 2006 Jul;16(3):248-52. doi: 10.1053/j.jrn.2006.04.006. J Ren Nutr. 2006. PMID: 16825030 Review.

10

Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.

Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM. Raggi P, et al. Among authors: burke sk. J Bone Miner Res. 2005 May;20(5):764-72. doi: 10.1359/JBMR.041221. Epub 2004 Dec 20. J Bone Miner Res. 2005. PMID: 15824849 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results